141 related articles for article (PubMed ID: 33831624)
41. Utilization of Autologous Hematopoietic Cell Transplantation Over Time in Multiple Myeloma: A Population-Based Study.
Esteghamat NS; Brunson A; Rosenberg AS; Schonfeld SJ; Valcarcel B; Abrahão R; Cooley JJP; Meyer CL; Auletta JJ; Morton LM; Muffly L; Wun T; Keegan THM
Clin Lymphoma Myeloma Leuk; 2024 Apr; 24(4):e119-e129. PubMed ID: 38195324
[TBL] [Abstract][Full Text] [Related]
42. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
43. Predictors of mortality after admission to pediatric intensive care unit in oncohematologic patients without history of hematopoietic stem cell transplantation: A single-center experience.
Pillon M; Sperotto F; Zattarin E; Cattelan M; Carraro E; Contin AE; Massano D; Pece F; Putti MC; Messina C; Pettenazzo A; Amigoni A
Pediatr Blood Cancer; 2019 Oct; 66(10):e27892. PubMed ID: 31250548
[TBL] [Abstract][Full Text] [Related]
44. Factors associated with prolonged stay in a pediatric emergency observation unit of an urban tertiary children's hospital in China.
Xie J; Lin Y; Kissoon N
Pediatr Emerg Care; 2013 Feb; 29(2):183-90. PubMed ID: 23364384
[TBL] [Abstract][Full Text] [Related]
45. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience.
Cao TM; Horning S; Negrin RS; Hu WW; Johnston LJ; Taylor TL; Shizuru JA; Hoppe RT; Brown BW; Blume KG; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2001; 7(5):294-301. PubMed ID: 11400952
[TBL] [Abstract][Full Text] [Related]
46. Impact of acute kidney injury and nephrotoxic exposure on hospital length of stay.
Searns JB; Gist KM; Brinton JT; Pickett K; Todd J; Birkholz M; Soranno DE
Pediatr Nephrol; 2020 May; 35(5):799-806. PubMed ID: 31940070
[TBL] [Abstract][Full Text] [Related]
47. Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma.
Laudi N; Arora M; Burns LJ; Miller JS; McGlave PB; Barker JN; Ramsay NK; Orchard PJ; Macmillan ML; Weisdorf DJ
Biol Blood Marrow Transplant; 2005 Feb; 11(2):129-35. PubMed ID: 15682074
[TBL] [Abstract][Full Text] [Related]
48. Length of Stay and Hospital Costs for Patients Undergoing Allogeneic Stem-Cell Transplantation.
Godara A; Siddiqui NS; Munigala S; Dhawan R; Kansagra AJ; Rapoport AP; Yared JA; Dahiya S
JCO Oncol Pract; 2021 Mar; 17(3):e355-e368. PubMed ID: 32735507
[TBL] [Abstract][Full Text] [Related]
49. Low CD34
Hyder MA; Goebel WS; Ervin KD; Schwartz JE; Robertson MJ; Thakrar TC; Albany C; Farag SS
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1497-1504. PubMed ID: 29410296
[TBL] [Abstract][Full Text] [Related]
50. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
Mannis GN; Martin TG; Damon LE; Andreadis C; Olin RL; Kong KA; Faham M; Hwang J; Ai WZ; Gaensler KML; Sayre PH; Wolf JL; Logan AC
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1030-1036. PubMed ID: 26899561
[TBL] [Abstract][Full Text] [Related]
51. Factors Affecting Length of Stay in Pediatric Emergency Department in a Teaching Hospital in Saudi Arabia.
Yousef AA; Al Qahtani MH; Al-Mutairi AK; AlQurashi FO; AlOmar RS; AlShamlan NA; Al Shammari MA; Yousef HA
Med Arch; 2023; 77(4):268-275. PubMed ID: 37876560
[TBL] [Abstract][Full Text] [Related]
52. Outcome of Allogeneic and Autologous Hematopoietic Cell Transplantation for High-Risk Peripheral T Cell Lymphomas: A Retrospective Analysis From a Chinese Center.
Huang H; Jiang Y; Wang Q; Guo L; Jin Z; Fu Z; Han Y; Sun A; Liu W; Ruan J; Wu D
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1393-1397. PubMed ID: 28478121
[TBL] [Abstract][Full Text] [Related]
53. A detailed analysis of charges for hematopoietic stem cell transplantation at a children's hospital.
Kline RM; Meiman S; Tarantino MD; Herzig RH; Bertolone SJ
Bone Marrow Transplant; 1998 Jan; 21(2):195-203. PubMed ID: 9489638
[TBL] [Abstract][Full Text] [Related]
54. Spinal fusion for pediatric neuromuscular scoliosis: national trends, complications, and in-hospital outcomes.
Rumalla K; Yarbrough CK; Pugely AJ; Koester L; Dorward IG
J Neurosurg Spine; 2016 Oct; 25(4):500-508. PubMed ID: 27203810
[TBL] [Abstract][Full Text] [Related]
55. Intraoperative Red Blood Cell Transfusion in Infant Heart Transplant Patients Is Not Associated with Worsened Outcomes.
Carter HF; Lau C; Juma D; Wells B; Applegate RL
Anesth Analg; 2016 May; 122(5):1567-77. PubMed ID: 27101500
[TBL] [Abstract][Full Text] [Related]
56. Invasive Mechanical Ventilation and Mortality in Pediatric Hematopoietic Stem Cell Transplantation: A Multicenter Study.
Rowan CM; Gertz SJ; McArthur J; Fitzgerald JC; Nitu ME; Loomis A; Hsing DD; Duncan CN; Mahadeo KM; Smith LS; Moffet J; Hall MW; Pinos EL; Cheifetz IM; Tamburro RF;
Pediatr Crit Care Med; 2016 Apr; 17(4):294-302. PubMed ID: 26910477
[TBL] [Abstract][Full Text] [Related]
57. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
[TBL] [Abstract][Full Text] [Related]
58. Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant.
Rosko AE; Huang Y; Benson DM; Efebera YA; Hofmeister C; Jaglowski S; Devine S; Bhatt G; Wildes TM; Dyko A; Jones D; Naughton MJ; Byrd JC; Burd CE
J Geriatr Oncol; 2019 May; 10(3):479-485. PubMed ID: 29983352
[TBL] [Abstract][Full Text] [Related]
59. Analysis of factors that influence neurosurgical length of hospital stay among newly diagnosed pediatric brain tumor patients.
Hasan M; Diep D; Manoranjan B; Maharaj A; Chaudhry S; Shaheen S; Farrokhyar F; Fleming AJ; Ajani O; Singh SK; Yarascavitch B
Pediatr Blood Cancer; 2020 Jan; 67(1):e28041. PubMed ID: 31612572
[TBL] [Abstract][Full Text] [Related]
60. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
